PDS Biotechnology Corp Operating Lease, Expense
PDS Biotechnology Corp (PDSB) reported Operating Lease, Expense of $241.03 thousand for the 12-month period ending 2022-12-31, per its 10-K filed 2023-03-28.
Discontinued › Expense Statement › Operating Expenses
us-gaap:OperatingLeaseExpense · last filed 2023-03-28
- PDS Biotechnology Corp operating lease, expense for the quarter ending 2019-12-31 was -$23.91K.
- PDS Biotechnology Corp operating lease, expense for the quarter ending 2019-09-30 was $98.65K.
- PDS Biotechnology Corp operating lease, expense for the quarter ending 2019-06-30 was $147.97K.
- PDS Biotechnology Corp operating lease, expense for the quarter ending 2019-03-31 was $24.66K.
- PDS Biotechnology Corp operating lease, expense for fiscal 2022 was $241.03K, a 0.00% decline from fiscal 2021.
- PDS Biotechnology Corp operating lease, expense for fiscal 2021 was $241.03K, a 50.00% increase from fiscal 2020.
- PDS Biotechnology Corp operating lease, expense for fiscal 2020 was $160.69K, a 35.04% decline from fiscal 2019.
- PDS Biotechnology Corp operating lease, expense for fiscal 2019 was $247.37K.
| Period end | Operating Lease, Expense 3 month | Operating Lease, Expense 6 month | Operating Lease, Expense 9 month | Operating Lease, Expense 12 month |
|---|---|---|---|---|
| 2022-12-31 | $241.03K 10-K · filed 2023-03-28 | |||
| 2021-12-31 | $241.03K 10-K · filed 2022-03-31 | |||
| 2020-12-31 | $160.69K 10-K · filed 2021-03-18 | |||
| 2019-12-31 | -$23.91K derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-27 | $74.73K derived: sum of 2 quarters · filed 2020-03-27 | $222.71K derived: sum of 3 quarters · filed 2020-03-27 | $247.37K 10-K · filed 2020-03-27 |
| 2019-09-30 | $98.65K 10-Q · filed 2019-11-07 | $246.62K derived: sum of 2 quarters · filed 2019-11-07 | $271.28K 10-Q · filed 2019-11-07 | |
| 2019-06-30 | $147.97K 10-Q · filed 2019-08-01 | $172.63K 10-Q · filed 2019-08-01 | ||
| 2019-03-31 | $24.66K 10-Q · filed 2019-05-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| SCYNEXIS INC (SCYX) | United States | $0.045B | |
| Grace Therapeutics, Inc. (GRCE) | $0.046B | -1.83 | |
| VERU INC. (VERU) | United States | $0.043B | -3.93 |
| Werewolf Therapeutics, Inc. (HOWL) | United States | $0.047B | |
| Kairos Pharma, LTD. (KAPA) | United States | $0.041B | |
| Dogwood Therapeutics, Inc. (DWTX) | United States | $0.049B | |
| Lite Strategy, Inc. (LITS) | United States | $0.049B | |
| Incannex Healthcare Inc. (IXHL) | $0.040B | -22.32 | |
| Elicio Therapeutics, Inc. (ELTX) | United States | $0.049B | |
| Karyopharm Therapeutics Inc. (KPTI) | United States | $0.039B | -0.98 |